Stockscreener 앱 받기
10.40
4.85%
-0.53
전일 마감가:
$10.93
열려 있는:
$11
하루 거래량:
848.44K
Relative Volume:
0.49
시가총액:
$1.33B
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-35.86
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
-9.25%
1개월 성능:
-7.88%
6개월 성능:
+36.84%
1년 성능:
+159.35%
1일 변동 폭
$10.32
$11.20
1주일 범위
$10.32
$11.46
52주 변동 폭
$3.9304
$14.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.40 | 1.40B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Can Trevi Therapeutics Inc. disrupt its industry2025 Earnings Surprises & Risk Adjusted Buy and Sell Alerts - mfd.ru
Growth Recap: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Trend Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Aug Outlook: How does Trevi Therapeutics Inc compare to its peersQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Advances Toward Treatment for Debilitating Cough - AD HOC NEWS
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Strong Buy Ratings and Nearly 100% Upside Potential - DirectorsTalk Interviews
Will Trevi Therapeutics Inc. benefit from rate cutsJuly 2025 Review & Technical Confirmation Trade Alerts - mfd.ru
Can Trevi Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
ETF Watch: Is Nabors Industries Ltd showing insider buyingTrade Exit Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Weekly Recap: Does Trevi Therapeutics Inc offer margin of safetyShort Setup & Verified High Yield Trade Plans - baoquankhu1.vn
Coulter Partners Recruits CFO for Trevi Therapeutics - Hunt Scanlon Media
Is Trevi Therapeutics Inc a momentum stockEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5%Here's Why - MarketBeat
Trevi Therapeutics (TRVI) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trevi Therapeutics Reports Positive Results on Treatment for Chronic Cough; Shares Rise - marketscreener.com
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PR Newswire
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? - Yahoo Finance
Peregrine Capital Management LLC Invests $5.68 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright - MarketBeat
Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News - GuruFocus
Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Sahm
Published on: 2026-01-09 09:26:05 - Улправда
Will Trevi Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & Long Hold Capital Preservation Plans - Улправда
Will Trevi Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Community Consensus Trade Alerts - Улправда
Growth Value: Can Trevi Therapeutics Inc. stock maintain growth trajectoryProfit Target & Verified Entry Point Signals - ulpravda.ru
Can Trevi Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Intraday Action & Reliable Breakout Stock Forecasts - Улправда
Sentiment Recap: Can TPIC stock surprise with earnings upsideJuly 2025 Earnings & Comprehensive Market Scan Insights - moha.gov.vn
Aug Shorts: Can Trevi Therapeutics Inc stock maintain growth trajectory2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
What dividend safety score for Trevi Therapeutics Inc. stockPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Trevi Therapeutics Outlines Key Development Milestones for Lead Drug Candidate - AD HOC NEWS
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):